Funding and Investments

Oct 12, 2017
By BioPharm International Editors
NIH has entered a five-year, $215-million collaboration with leading biopharmaceutical companies to advance the development of cancer immunotherapies.
Oct 08, 2015
Through the Glycoscience Program, the National Institute of Health will contribute $10 million to advance the study of carbohydrates and the compounds that interact with them.
Sep 22, 2015
By BioPharm International Editors
Six grants from the NIH will help identify variants in the genome’s regulatory regions that affect disease risk, using new computational approaches.
Dec 01, 2014
BioPharm International
By BioPharm International Editors
Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.
Oct 24, 2014
Unum Therapeutics raised $12 million in Series A funding for its development of antibody-coupled T cell receptors (ACTRs) for the treatment of nonspecific tumor cells.
Jul 02, 2014
By BioPharm International Editors
OCE and OBI partner with CQDM on $3 million inter-provincial drug discovery innovation programs.
Jul 01, 2014
BioPharm International
By BioPharm International Editors
Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.
Apr 22, 2014
By BioPharm International Editors
Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.
Apr 01, 2014
BioPharm International
By BioPharm International Editors
Life-sciences companies continue upward momentum in 2014.
Jan 01, 2014
BioPharm International
By BioPharm International Editors
Frenzy cools as investors seeking a quick return turn elsewhere.
native1_300x100
lorem ipsum